Mezlocillin

Mezlocillin

Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Pregnancy category	B
Routes of administration	Intravenous, intramuscular
ATC code	J01CA10 (WHO)
Pharmacokinetic data
Protein binding	16–59%
Metabolism	Hepatic (20–30%)
Elimination half-life	1.3–4.4 hours
Excretion	Renal (50%) and biliary
Identifiers
IUPAC name (2S,5R,6R)-3,3-dimethyl-6-[[(2R)-2-[(3-methylsulfonyl- 2-oxo-imidazolidine-1-carbonyl)amino]-2-phenyl-acetyl] amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2- carboxylic acid
CAS Number	51481-65-3 Y
PubChem CID	656511
DrugBank	DB00948 Y
ChemSpider	570894 Y
UNII	OH2O403D1G
KEGG	D05021 Y
ChEBI	CHEBI:6919 Y
ChEMBL	ChEMBL1731 Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C21H25N5O8S2
Molar mass	539.584 g/mol
3D model (JSmol)	Interactive image
SMILES O=C(O)[C@@H]3N4C(=O)[C@@H](NC(=O)[C@@H](c1ccccc1)NC(=O)N2C(=O)N(S(=O)(=O)C)CC2)[C@H]4SC3(C)C
InChI InChI=1S/C21H25N5O8S2/c1-21(2)14(18(29)30)26-16(28)13(17(26)35-21)22-15(27)12(11-7-5-4-6-8-11)23-19(31)24-9-10-25(20(24)32)36(3,33)34/h4-8,12-14,17H,9-10H2,1-3H3,(H,22,27)(H,23,31)(H,29,30)/t12-,13-,14+,17-/m1/s1 Y Key:YPBATNHYBCGSSN-VWPFQQQWSA-N Y
(verify)

WikiDoc Resources for Mezlocillin
Articles
Most recent articles on Mezlocillin Most cited articles on Mezlocillin Review articles on Mezlocillin Articles on Mezlocillin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Mezlocillin Images of Mezlocillin Photos of Mezlocillin Podcasts & MP3s on Mezlocillin Videos on Mezlocillin
Evidence Based Medicine
Cochrane Collaboration on Mezlocillin Bandolier on Mezlocillin TRIP on Mezlocillin
Clinical Trials
Ongoing Trials on Mezlocillin at Clinical Trials.gov Trial results on Mezlocillin Clinical Trials on Mezlocillin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Mezlocillin NICE Guidance on Mezlocillin NHS PRODIGY Guidance FDA on Mezlocillin CDC on Mezlocillin
Books
Books on Mezlocillin
News
Mezlocillin in the news Be alerted to news on Mezlocillin News trends on Mezlocillin
Commentary
Blogs on Mezlocillin
Definitions
Definitions of Mezlocillin
Patient Resources / Community
Patient resources on Mezlocillin Discussion groups on Mezlocillin Patient Handouts on Mezlocillin Directions to Hospitals Treating Mezlocillin Risk calculators and risk factors for Mezlocillin
Healthcare Provider Resources
Symptoms of Mezlocillin Causes & Risk Factors for Mezlocillin Diagnostic studies for Mezlocillin Treatment of Mezlocillin
Continuing Medical Education (CME)
CME Programs on Mezlocillin
International
Mezlocillin en Espanol Mezlocillin en Francais
Business
Mezlocillin in the Marketplace Patents on Mezlocillin
Experimental / Informatics
List of terms related to Mezlocillin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Mezlocillin is a broad-spectrum penicillin antibiotic. It is active against both Gram-negative and some Gram-positive bacteria. Unlike most other extended spectrum penicillins, it is excreted by the liver, therefore it is useful for biliary tract infections, such as ascending colangitis.

Mechanism of action

Main article: Beta-lactam antibiotic

Like all other beta-lactam antibiotics, mezlocillin inhibits the third and last stage of bacterial cell wall synthesis by binding to penicillin binding proteins. This ultimately leads to cell lysis.

Susceptible organisms

Gram-negative

• Bacteroides spp., including B. fragilis
• Enterobacter spp.
• Escherichia coli
• Haemophilus influenzae
• Klebsiella species
• Morganella morganii
• Neisseria gonorrhoeae
• Proteus mirabilis
• Proteus vulgaris
• Pseudomonas spp., including P. aeruginosa
• Serratia marcescens

Gram-positive

• Enterococcus faecalis
• Peptostreptococcus spp.

External links

• Template:DiseasesDB
• Template:GPnotebook
• Duke
• Kristof R, Clusmann H, Koehler W, Fink K, Schramm J (1998). "Treatment of accidental high dose intraventricular mezlocillin application by cerebrospinal fluid exchange". J Neurol Neurosurg Psychiatry. 64 (3): 379–81. doi:10.1136/jnnp.64.3.379. PMC 2170014. PMID 9527154.CS1 maint: Multiple names: authors list (link)
• McCormick P, Greenslade L, Kibbler C, Chin J, Burroughs A, McIntyre N (1997). "A prospective randomized trial of ceftazidime versus netilmicin plus mezlocillin in the empirical therapy of presumed sepsis in cirrhotic patients". Hepatology. 25 (4): 833–6. doi:10.1002/hep.510250408. PMID 9096584.CS1 maint: Multiple names: authors list (link)
• Rohde B, Werner U, Hickstein H, Ehmcke H, Drewelow B (1997). "Pharmacokinetics of mezlocillin and sulbactam under continuous veno-venous hemodialysis (CVVHD) in intensive care patients with acute renal failure". Eur J Clin Pharmacol. 53 (2): 111–5. doi:10.1007/s002280050347. PMID 9403281.CS1 maint: Multiple names: authors list (link)